French pharmaceutical and healthcare company Sanofi on Friday announced a share buyback plan worth up to €2 billion ($2.08 ...

The French drugmaker said it had entered a mandate with an “investment service provider”, with the purchase occurring between ...

According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

Sanofi (SNY), a French pharmaceutical and healthcare company, Friday announced that it is executing the second tranche of its share ...

Execution of a share buyback agreement for up to €2 billion Paris, February 7, 2025. On January 30, 2025 ( Sanofi ...

Execution of a share buyback agreement for up to €2 billionParis, February 7, 2025. On January 30, 2025, Sanofi announced its intention to ...

As previously reported, L’Oréal sales in the three months ended Dec. 31 reached 11.08 billion euros, up 4.5 percent in ...

Shares in French cosmetics giant L'Oreal fell by more than 4% in early trade on Friday after the company posted its slowest ...

Sanofi announced its intention to execute a share buyback program in 2025 of €5 billion, preferably through block trades and in the open market with the purpose of cancellation. A first tranche of ...

Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego: Paris Friday, February 7, 2025, 12 ...

Cendakimab fell short of the bar. The antibody hits IL-13, one of the interleukins targeted by Regeneron and Sanofi’s ...

Evaluate’s latest analysis forecasts an $82 billion increase in major product revenues in 2025 – the largest annual growth ...